Further studies on RCCs with prior antiangiogenic therapy have to investigate if MET amplification is seen in therapy resistant RCCs, resembling a resistance mechanism evident in lung cancers with EGFR activating mutations treated with Gefitinib [47]. Here, EGFR is linked to lung cancer.